Abemaciclib has been approved in the USA for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, in combination with fulvestrant in women with disease......
Wyld, L. et al. Prognostic factors for patients with hepatic metastases from breast cancer.Br. J. Cancer89, 284–290 (2003). ArticleCASGoogle Scholar Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of th...
The median number of prior therapies for advanced or metastatic breast cancer was 2 (range, 1-3) for cohort 1, 2 (range, 1-4) for cohort 2, and 2 (range, 1-6) for cohort 3. Prior lines of endocrine therapy in the advanced/metastatic setting included 1 (cohort 1, 60%; cohort 2...
abemaciclib/内分泌治疗组的 2 年无远期复发生存率为 93.8%,而单独内分泌治疗组为 90.8%。 参考来源:NICE Recommends Abemaciclib for HR+/HER2– Advanced Breast Cancer 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护...
Analysis of renal function in MONARCH 1: A phase 2study of abemaciclib, a CDK4 & 6 inhibitor, asmonotherapy, in patients with HR /HER2- breastcancer, after chemotherapy for metastatic breastcancer (MBC), San Antonio Breast Cancer Symposium.Cancer Res 77, 2017 (4 suppl; abstract P6-15-01...
参考来源:US FDA broadens indication for Verzenio® (abemaciclib) in HR+, HER2-, node-positive, high risk early breast cancer. News release. Eli Lilly and Company. Accessed March 3, 2023. 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助...
[1]Z. Jiang,X. Hu,Q.Zhang. et al. A Phase III Trial of Abemaciclib plus Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant (F) for Women with HR+/HER2- Advanced Breast Cancer (ABC).2019 ESMO LBA 25 [2]Xichun Hu, Nong Yang, Jian Zhang, et al. A phase 1 study of abemacicli...
1.Di Leo A, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer. Presented at: 2017 ESMO Congress; Madrid, Spain; September 8-12, 2017. Abstract 236O_PR 2.https://investor.lilly.com/releasedetail.cfm?ReleaseID=1058732...
DOI:10.1200/JCO.2017.73.7585PMID:28580882URL [本文引用:2] [7]GOETZ MP,TOIM,CAMPONEM,et al.MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol ,2017,35(32):3638-3646. DOI:10.1200/JCO.2017.75.6155PMID:28968163URL [本文引用:15]...
these drugs are also on the PBS for specific types ofbreast cancer. As the drugs differ in their chemical structures, they haveslight differencesin the way they are taken up and processed by the body. The preferred drug given to a breast cancer patient will depend on their unique ...